If you or someone you love is diagnosed with advanced uveal melanoma, a rare cancer that starts in the eye, you know how few good treatment options exist. This study asked a critical question for a specific group of patients: could a new, targeted drug help them live longer than the standard treatments doctors already use? The trial focused on adults with a specific genetic marker (HLA-A*0201 positive) who had not yet received any treatment for their advanced cancer. They were randomly assigned to receive either the new drug, called IMCgp100, or one of three other treatments chosen by their doctor: dacarbazine, ipilimumab, or pembrolizumab. The main goal was to see which group had better overall survival. The study also looked at other important measures, like how long the cancer stayed under control and how many patients saw their tumors shrink. The results directly compare the survival benefit of this new approach against the current standard of care, providing clear evidence for patients and doctors facing this difficult diagnosis.
Phase II trial compares IMCgp100 vs investigator choice in advanced uveal melanomaCan a new drug help people with a rare eye cancer live longer?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Review Phase II data comparing IMCgp100 to investigator choice in advanced uveal melanoma.
This Phase II study compared the safety and efficacy of IMCgp100 with investigator's choice of dacarbazine, ipilimumab, or pembrolizumab in HLA-A*0201 positive adult patients with advanced uveal melanoma. The study enrolled 378 patients who were previously untreated in the advanced setting, with no prior systemic or liver-directed chemo-, radio-, or immune-therapy allowed (prior surgical resection of liver metastases and adjuvant systemic therapy were acceptable). The study was conducted from October 16, 2017, to October 13, 2020, with results posted on September 14, 2021. The primary endpoint was overall survival, with secondary efficacy endpoints including progression-free survival, objective response rate, duration of response, and disease control rate. The abstract does not provide specific numerical results for these endpoints, safety data, or statistical comparisons between the treatment arms.
What this means for you:
A new drug was tested head-to-head against existing treatments for advanced eye cancer to see which helps patients live longer. More on Uveal Melanoma
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
PD-1/PD-L1 inhibitors improve response in dMMR/MSI-H metastatic colorectal cancer
New meta-analysis shows PD-1 inhibitors improve response rates for dMMR colorectal cancer
This meta-analysis of 1460 patients with dMMR/MSI-H metastatic colorectal cancer found that PD-1/PD-L1 monotherapy significantly improved ob…
A large review of 1460 patients found PD-1 inhibitors significantly improved tumor response rates compared to chemotherapy for dMMR colorect…
Immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4 show improved risk discrimination for immune-toxicity-associated systemic injury
New Tool Predicts Immune Drug Organ Damage
This translational multicohort study evaluated patients receiving immune checkpoint inhibitors in United States electronic health record dat…
A new system helps doctors predict which patients might suffer dangerous organ injury from powerful cancer drugs, giving them time to act so…
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
View Original Abstract ↓
Status: COMPLETED | Phase: PHASE2
Condition(s): Uveal Melanoma
Intervention(s): IMCgp100 (BIOLOGICAL), Dacarbazine (DRUG), Ipilimumab (BIOLOGICAL), Pembrolizumab (BIOLOGICAL)
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
Detailed: This Phase II study is designed to evaluate the safety and efficacy of IMCgp100 compared with Investigator's Choice (dacarbazine, ipilimumab or pembrolizumab) in HLA-A\*0201 positive adult patients with advanced UM treated in the first line setting with no prior systemic or liver-directed chemo-, radio- or immune-therapy administered in the advanced setting (prior surgical resection of liver metastases and adjuvant systemic therapy are acceptable). Comparison of the IMCgp100 efficacy results in this Phase II study will be made with the concurrently randomized arm (Investigator's Choice) with a primary endpoint of overall survival (OS) and secondary efficacy endpoints of progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and disease control rate (DCR
Primary Outcome(s): Efficacy: Overall Survival
Enrollment: 378 (ACTUAL)
Lead Sponsor: Immunocore Ltd
Start: 2017-10-16 | Primary Completion: 2020-10-13
Results posted: 2021-09-14
Guselkumab Phase III trials validate 3VAS and 4VAS measures for psoriatic arthritis disease activity assessment
Study checks how well pain scores track joint damage in psoriatic arthritis patients
Related in Dermatology
Nemolizumab Q4W improves IGA success maintenance by 11.8% over withdrawal in atopic dermatitis
Trial shows nemolizumab maintains skin results for atopic dermatitis
This Phase 3 randomized controlled trial evaluated nemolizumab in 507 adolescents and adults with moderate-to-severe atopic dermatitis who w…
A new trial found that nemolizumab helps maintain clear skin and reduce itching for adults and teens with moderate to severe atopic dermatit…
SSGJ-608 achieves 92.7% to 95.1% PASI75 response in moderate-to-severe plaque psoriasis
New injection shows promise for moderate to severe plaque psoriasis
This phase 3 randomized trial in 770 patients with moderate-to-severe plaque psoriasis found that SSGJ-608 (80mg every 2 weeks or 160mg ever…
A new injectable treatment showed high success rates in clearing skin and improving appearance for people with plaque psoriasis.
Operating room nurses describe critical trauma management challenges and teamwork dynamics in a qualitative review
Nurses share how trauma care shapes their daily work and personal lives
Fifteen experienced trauma nurses shared their lived experiences managing critical multiple injuries in a tertiary Hunan hospital. Their nar…
Fifteen experienced nurses describe the professional challenges, teamwork dynamics, and stress they face while managing critical trauma case…
FDA Approves Tremfya (guselkumab) for Ulcerative Colitis and Crohn's Disease
FDA approves Tremfya for ulcerative colitis and Crohn's disease.
The FDA approved Tremfya (guselkumab) for adults with moderately to severely active ulcerative colitis and Crohn's disease. The approval exp…
The FDA approved Tremfya (guselkumab) for adults with moderate to severe ulcerative colitis or Crohn's disease. It is the first drug of its …
From Other Specialties
Fibromyalgia as an oncology comorbidity increases symptom burden and impairs treatment adherence
Fibromyalgia makes managing cancer pain more difficult for patients
This systematic review of 11 studies examines fibromyalgia as a comorbidity in cancer patients. The findings indicate that fibromyalgia cont…
Patients with both fibromyalgia and cancer face higher symptom burdens and may stop life-saving treatments sooner due to intense, amplified …
Physical exam algorithm distinguishes benign anal masses, guides surgical decisions
New Clinical Algorithm Helps Identify Anal Masses and Prolapse
This narrative review proposes a clinical decision algorithm based on physical examination to differentiate benign lesions prolapsing throug…
Doctors can now use a specific physical examination guide to tell the difference between rectal prolapse, hemorrhoids, and other anal condit…
Individualized six-phase antithrombotic strategy leads to left ventricular thrombus resolution and neurological recovery
New strategy helps manage heart blood clots after heart attack
This case report describes an individualized six-phase antithrombotic strategy for a 27-year-old male with myocardial infarction, stroke, hy…
A tailored six-phase treatment plan helped a young man recover fully from a stroke and heart attack while successfully clearing dangerous bl…
Heterogeneous definitions and clinical inconsistencies currently hinder the accurate identification of treatment-resistant depression
New ways to define treatment resistant depression are emerging
This narrative review examines the phenotypic definition of treatment-resistant depression (TRD) and its associated biological correlates. T…
Doctors struggle to treat some types of depression because the current definition is inconsistent. New research looks at how biology and beh…